newsfilter
← Latest News
Business Wire·

KYTHERA Biopharmaceuticals Announces Results from Open-Label Study for ATX-101

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced interim study results from Study ATX-101-11-26, a multicenter, open-label, long-term study to evaluate the safety of ATX-101, a facial injectable drug for the reduction of submental fat (SMF), which commonly presents as an unwanted double chin.